Cover Image

Evaluation of Individual and Trial Level Association Metrics in the Validation of a Binary Surrogate Endpoint for a True Time-to-Event Endpoint

Fuente: arXiv

Saved in:

Bibliographic Details
Main Authors:	Ge, Renee Y., Shohoudi, Azadeh, Iyengar, Malini, Li, Quefeng, Li, Judy
Format:	Preprint
Published:	2026
Subjects:	Applications
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of Minimal Residual Disease as a Surrogate for Progression-Free Survival in Hematology Oncology Trials: A Meta-Analytic Review
by: She, Jane, et al.
Published: (2026)

Evaluation of Surrogate Endpoints Based on Meta-Analysis with Surrogate Indices
by: Stijven, Florian, et al.
Published: (2025)

Fragility Index for Time-to-Event Endpoints in Single-Arm Clinical Trials
by: Maity, Arnab Kumar, et al.
Published: (2024)

Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
by: Long, James P., et al.
Published: (2025)

Tutorial for Surrogate Endpoint Validation Using Joint modeling and Mediation Analysis
by: Coent, Quentin Le, et al.
Published: (2025)

Multiple Imputation for Small, Extremely High Efficacy Clinical Trials with Binary Endpoints
by: Tan, Yaoyuan Vincent, et al.
Published: (2025)

Toward Valid Generative Clinical Trial Data with Survival Endpoints
by: Chassat, Perrine, et al.
Published: (2025)

Study Duration Prediction for Clinical Trials with Time-to-Event Endpoints Using Mixture Distributions Accounting for Heterogeneous Population
by: Zhang, Hong, et al.
Published: (2023)

A Reflection on the Impact of Misspecifying Unidentifiable Causal Inference Models in Surrogate Endpoint Evaluation
by: Deliorman, Gokce, et al.
Published: (2024)

Power and Sample Size Calculations for Bayes Factors in two-arm clinical Phase II Trials with binary Endpoints
by: Kelter, Riko
Published: (2026)

Optimal sequential two-stage Bayes Factor Design for two-arm clinical Phase II Trials with binary Endpoints
by: Kelter, Riko
Published: (2026)

A Utility Score Framework for Dose Optimization Studies with Binary Efficacy-Safety Endpoints: Sample Size Determination and Bias Characterization
by: Gu, Xuemin, et al.
Published: (2026)

Estimation and Inference for Win Measures with Multiple Ordinal Endpoints Subject to Missingness
by: Liu, Yi, et al.
Published: (2026)

Matrix-Response Generalized Linear Mixed Model with Applications to Longitudinal Brain Images
by: Yu, Zhentao, et al.
Published: (2026)

Estimation and Inference of the Win Ratio for Two Hierarchical Endpoints Subject to Censoring and Missing Data
by: Liu, Yi, et al.
Published: (2026)

Multi-Dimensional Composite Endpoint Analysis via the Choquet Integral: Block Recurrent Encoding and Comparative Advantage Mapping
by: Tanboga, Ibrahim Halil
Published: (2026)

Correcting for Missing Data When Evaluating Surrogate Markers in a Clinical Trial
by: Lotspeich, Sarah C., et al.
Published: (2026)

Causal Judge Evaluation: Calibrated Surrogate Metrics for LLM Systems
by: Landesberg, Eddie, et al.
Published: (2025)

Adaptive Designs in Trials With Time‐to‐Event Endpoints and Covariate Adjustment
by: Daniel Backenroth, et al.
Published: (2026)

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints
by: Jingya Gao, et al.
Published: (2024)

Evaluating Organizational Effectiveness: A New Strategy to Leverage Multisite Randomized Trials for Valid Assessment
by: Hong, Guanglei, et al.
Published: (2024)

Analyzing Population-Level Trials as N-of-1 Trials: an Application to Gait
by: Zhou, Lin, et al.
Published: (2022)

Prediction Intervals for Interim Events in Randomized Clinical Trials with Time-to-Event Endpoints
by: Ratti, Edoardo, et al.
Published: (2026)

An Integrated Time-Varying Ornstein-Uhlenbeck Process for Jointly Modeling Individual and Population-Level Movement of Golden Eagles
by: Shull, Michael L., et al.
Published: (2025)

Unified and Simple Sample Size Calculations for Individual or Cluster Randomized Trials with Skewed or Ordinal Outcomes
by: Tu, Shengxin, et al.
Published: (2025)

Surrogate Endpoints in Regulatory Decision‐Making
by: Linda J. B. Jeng, et al.
Published: (2025)

On the Role of Surrogates in Conformal Inference of Individual Causal Effects
by: Gao, Chenyin, et al.
Published: (2024)

Penalized Likelihood Optimization for Adaptive Neighborhood Clustering in Time-to-Event Data with Group-Level Heterogeneity
by: Ragni, Alessandra, et al.
Published: (2026)

Unveiling True Talent: The Soccer Factor Model for Skill Evaluation
by: Andorra, Alexandre, et al.
Published: (2024)

Two-Part Forecasting for Time-Shifted Metrics
by: Katz, Harrison, et al.
Published: (2025)

Estimation of Heterogeneous Causal Mediation Effects in a Hypertension Treatment Trial
by: Zhao, Yi, et al.
Published: (2025)

Time‐to‐Event Endpoints in Imaging Biomarker Studies
by: Ruizhe Chen, et al.
Published: (2024)

Evaluating the Surrogate Index as a Decision-Making Tool Using 200 A/B Tests at Netflix
by: Zhang, Vickie, et al.
Published: (2023)

A Federated Data Analysis Approach for the Evaluation of Surrogate Endpoints
by: Dries De Witte, et al.
Published: (2025)

E-values for Adaptive Clinical Trials: Anytime-Valid Monitoring in Practice
by: Sokolova, Alexandra, et al.
Published: (2026)

Signed Rank Chart For Tied Observations: An Application of Deep Learning Models
by: Mortezanejad, Seyedeh Azadeh Fallah, et al.
Published: (2025)

Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials
by: Guotao Chu, et al.
Published: (2025)

Deep Learning Surrogates for Real-Time Gas Emission Inversion
by: Newman, Thomas, et al.
Published: (2025)

A Comprehensive Framework for Evaluating Time to Event Predictions using the Restricted Mean Survival Time
by: Cwiling, Ariane, et al.
Published: (2023)

Personalized Oncology: Feasibility of Evaluating Treatment Effects for Individual Patients
by: Jang, Lydia, et al.
Published: (2025)